Medical Journals

A Crosstalk Between Myeloma Cells and Marrow Stromal Cells Stimulates Production of Dkk1 and Interleukin-6: a Potential Role in the Development of Lytic Bone Disease and Tumor Progression in Multiple Myeloma.

Authors:
  • Gunn William G
  • Conley Adam
  • Deininger Lisa
  • Olson Scott D
  • Prockop Darwin J
  • Gregory Carl A

From: Center for Gene Therapy, Tulane University Health Sciences Center, New Orleans, Louisiana, USA.

Stem cells (Dayton, Ohio)

  • Publish Date: Apr 2006
  • ISSN: 1066-5099
  • Volume: 24
  • Issue: 4
  • Pages: 986-91
  • Medium: Print
  • Language: English
  • Citation (JAMA): Gunn William G, Conley Adam, Deininger Lisa, et al. A Crosstalk Between Myeloma Cells and Marrow Stromal Cells Stimulates Production of Dkk1 and Interleukin-6: a Potential Role in the Development of Lytic Bone Disease and Tumor Progression in Multiple Myeloma.. Stem Cells Apr 2006;24:986-91

Abstract

Multiple myeloma (MM) is a malignancy of antibody-secreting plasma cells. B-cell plasmacytomas stimulate bone resorption and angiogenesis, resulting in osteolytic lesions in the skeleton which persist upon successful treatment of the malignancy with chemotherapy. We found that an interaction between MM cells and mesenchymal stem cells (MSCs) from bone marrow stroma results in the formation and persistence of osteolytic bone lesions. It is known that MM cells activate osteoclast activity and secrete high levels of the Wnt inhibitor, Dickkopf-1, which prevents MSCs from differentiating into osteoblasts. We show that the Wnt signaling activator 6-bromoindirubin-3’-monoxime (BIO) releases MSCs from the osteoinhibitory effects of Dickkopf-1, whereas LiCl treatment does not. Additionally, we show that the >5-kDa fraction of MSC-conditioned medium promotes the proliferation of Dickkopf-1-secreting MM cells and that an interleukin-6 (IL-6)-neutralizing antibody blocks this effect. IL-6 expression levels were higher in undifferentiated MSCs than in MSCs treated with osteogenic medium, remained high in the presence of Dkk1, and were reduced by BIO treatment. Therefore, BIO treatment reduces the MSC-stimulated proliferation of MM cells and may enable MSCs to repair existing osteolytic lesions.

Mesh Headings (Keywords): Bone Marrow Cells, Cell Communication, Cell Differentiation, Cell Line, Tumor, Cells, Cultured, Culture Media, Conditioned, Gene Expression, Humans, Intercellular Signaling Peptides and Proteins, Interleukin-6, Models, Biological, Multiple Myeloma, Osteogenesis, Osteolysis, RNA, Messenger, Stromal Cells


Check for Full Text / PubMed Unique Identifier (PMID): 16293576


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.